OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Clinical Dermatology is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Alcohol and Smoking Cessation as Potential Modulators for Smoking-Associated Psoriasis Risk in Postmenopausal Women: The Women’s Health Initiative	196
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review	156
Prognostic Biomarkers in Evolving Melanoma Immunotherapy	106
Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions	93
The Current State of Systemic Therapy of Metastatic Uveal Melanoma	87
Economic Burden of Chronic Hand Eczema: A Review	86
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments	83
Disease Duration in Patients Recruited to Psoriasis Phase III Trials: A Systematic Review	79
Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments	77
The Burden of Pediatric Psoriasis: A Systematic Review	77
Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know	60
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study	58
Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology	58
Performance of Staging Systems for Non-head and Neck Cutaneous Squamous Cell Carcinoma	58
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data	57
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?	56
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review	54
Agreement Between Nail Psoriasis Severity Index Scores by a Convolutional Neural Network and Dermatologists: A Retrospective Study at an Academic New York City Institution	54
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks	54
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroi	51
Pathophysiology of Generalized Pustular Psoriasis	51
Disease Modification in Psoriasis: Future Prospects for Long-Term Remission	50
Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion	50
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation	49
Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study	47

Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment	46
Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”	46
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management	41
Skin Cancer in People of Color: A Systematic Review	41
Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature	41
Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis	41
Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry	41
Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives	41
Lessons Learned from Orthopedics: A Call to Action for More Rigorous Platelet-Rich Plasma Hair Loss Clinical Trials	41
A Practice Approach to Acne Fulminans in Adolescents	40
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis	39
Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment	38
Correction to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment Hist	37
Ethnic Differences of Palmoplantar Pustulosis: A Systematic Review	37
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa	37